Jamie Michael

Dr. Jamie Michael


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
ESElizabeth Snyder
Elizabeth Snyder
CMCharan Mohan
Charan Mohan
JMJamie Michael
Jamie Michael
SRSherry Ross
Sherry Ross

8 November 2024 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
JMJamie Michael
Jamie Michael
PXPerry Xu
Perry Xu
NDNick Dean
Nick Dean
MGMeera Ganesh
Meera Ganesh
KTKyle Tsai
Kyle Tsai
AKAmy Krambeck
Amy Krambeck

31 July 2025 in Urology
Verified
Journal Article
Closed access
JMJamie Michael
Jamie Michael
DGDaniel R. Greenberg
Daniel R. Greenberg
MAMona Ascha
Mona Ascha
CGChristopher D. Gonzales-Alabastro
Christopher D. Gonzales-Alabastro
KWKeith Weissman
Keith Weissman
DBDiana K. Bowen
Diana K. Bowen

20 June 2025 in The Prostate
Verified
Journal Article
Open access
JMJamie Michael
Jamie Michael
ELEric V. Li
Eric V. Li
MHMitch Huang
Mitch Huang
NHNicole Handa
Nicole Handa
NKNalin Kundu
Nalin Kundu
ARAshley E. Ross
Ashley E. Ross
Background: Genomic biomarkers offer opportunities to improve risk stratification for patients with prostate cancer. We performed a transcriptomic profile of active surveillance (AS)‐eligible patients who underwent radical prostatectomy (RP) to understand genomic associations with adverse pathologic features (APF) at RP.Methods: Patients considered AS‐eligible (NCCN low‐favorable intermediate risk) but proceeded to RP from February 2012 to September 2024 were identified from our prospective institutional database. Outcomes were classified by presence or absence of APF at RP, which was defined as grade group (GG) ≥ 3, pT3b, or pN1 disease. Previously established genomic signatures of interest were compared between the two groups. Scaled multivariable logistic regression was performed to evaluate associations between multiple genomic classification systems and the outcome of APF.Results: There were 184 AS‐eligible patients, of whom 153 (83.2%) had favorable intermediate risk disease and 31 (16.8%) had low risk disease. There were 41 patients (22.3%) who had APF at RP. The incidence of favorable intermediate risk disease did not differ between those with and without APF (80.5% vs. 83.9%, p = 0.64). Patients with APF had a higher baseline PSA (5.6 ng/mL vs. 4.9 ng/mL, p = 0.01) and Decipher score (0.55 vs. 0.41, p = 0.004) compared to those without APF. On scaled logistic regression with adjustment for log‐transformed PSA, the Decipher score, PTEN loss, activated CD4, and ERG positive rate were significantly associated with APF (OR 1.61, 95% CI 1.11–2.32, p = 0.01). Of ten other previously published genomic classifiers, nine were significantly associated with APF.Conclusion: AS‐eligible patients with APF at RP demonstrate differences in gene expression when compared to those without APF. We established that multiple existing genomic classifiers not previously studied in this context demonstrate the ability to predict APF in this patient population. Inclusion of genomics in the risk stratification of AS‐eligible patients has the potential to better inform clinical decisions.

9 October 2024 in Case Reports in Women's Health
Verified
Journal Article
Open access
JMJamie Michael
Jamie Michael
HKHebron Kelecha
Hebron Kelecha
DBDiana Bowen
Diana Bowen
AWAmber Watters
Amber Watters
Due to advancements in medical care and reconstructive surgery, more patients with bladder exstrophy are reaching reproductive age and considering pregnancy. Complications are more common during pregnancy in this patient population, given medical comorbidities and prior surgical intervention. In the case of cesarean delivery, careful planning is necessary to prevent inadvertent injury to the bladder or bowel segments. This report concerns a patient with a history of infant closure of bladder exstrophy, followed by two bladder augmentations and a catheterizable channel who presented for care at 9 weeks of gestation. Magnetic resonance imaging (MRI) at 36 weeks of gestation was used to delineate the anatomy in planning for cesarean delivery. The patient underwent a successful cesarean delivery at 38 weeks 1 day of gestation. Patients with prior urologic reconstruction can undergo safe cesarean delivery if proper surgical planning is performed. Multidisciplinary care and prenatal MRI are valuable tools for avoiding surgical complications.

JMJamie Michael
Jamie Michael
VWVivian Wan
Vivian Wan
KSKirtana Sandepudi
Kirtana Sandepudi
SJSumanas Jordan
Sumanas Jordan
DBDiana K. Bowen
Diana K. Bowen
Current literature on baseline voiding function in gender-diverse patients assigned male at birth (AMAB) is limited. We conducted a retrospective analysis of patients presenting for gender-affirming orchiectomy consultation between 2021 and 2024 who completed the American Urological Association symptom score (AUA-SS) questionnaire to characterize baseline urinary symptoms and identify factors associated with symptom-related bother. Demographics, hormone therapy characteristics, and comorbidities were collected. Bother score was analyzed as both an ordinal variable (score 0 = “delighted” to 6 = “terrible”) and dichotomized (no bother = “delighted” or “pleased” and some bother = “mostly satisfied” to “terrible”). Twenty-six patients met the inclusion criteria, with a median age of 28 years. Overall symptom burden was low (median AUA-SS 4, IQR 2–7.3), with frequency and nocturia reported most commonly. Despite mild symptoms, most patients did not select the lowest possible bother score (“delighted”). Total AUA-SS and bother were not significantly associated with hormone therapy type or duration. In contrast, those with a documented history of anxiety, depression, or bipolar disorder had significantly higher bother score compared to those without (mean rank 15.3 vs. 9.6, p = 0.04). In this single-center cohort, urinary symptoms were generally mild among AMAB patients seeking gender-affirming orchiectomy. Psychiatric history was associated with a higher bother score, though this relationship was no longer significant when bother was dichotomized. These findings suggest behavioral factors may influence how urinary symptoms are experienced and reported in this population. These findings are exploratory and warrant validation in larger cohorts.